|
Outcomes
|
Mean of proportions across the three sites (SD)
|
% Increase
|
Pvalue†
|
|---|
|
Baseline
|
Intervention
|
|---|
|
Initiation of BMD testing
|
2.79 (1.27)
|
6.15 (2.24)
|
3.4
|
<0.001
|
|
95% CI
|
1.86 to 3.74
|
3.38 to 8.42
|
2.03 to 4.68
|
|
Initiation of any osteoporosis medication
‡
|
0.42 (0.36)
|
0.87 (0.66)
|
0.5
|
0.006
|
|
95% CI
|
0 to 1.13
|
0 to 2.16
|
0.15 to 0.85
|
|
Initiation of calcium + vitamin D
|
0.70 (0.56)
|
1.58 (0.95)
|
0.9
|
<0.001
|
|
95% CI
|
0 to 1.80
|
0 to 3.44
|
0.39 to 1.41
|
|
Initiation of any nutritional supplement (calcium or vitamin D)
|
0.97 (0.71)
|
2.13 (1.28)
|
1.2
|
0.001
|
|
95% CI
|
0 to 2.36
|
0 to 4.64
|
0.49 to 1.91
|
- *BMD, bone mineral density; SD, standard deviation.
-
†From autoregressive integrated moving-average (ARIMA) model. Intercept only model is fitted since the slopes are not significantly different from zero.
-
†The following osteoporosis medications were considered: any bisphosphonate (alendronate, etidronate, risedronate, zoledronic acid), any selective estrogen receptor modulator (e.g., raloxifene), nasal calcitonin, parathyroid hormone, and hormone replacement therapy.
